Pharmaron prices $588m Hong Kong IPO at top end
Pharmaceutical research and development platform Pharmaron Beijing Co has bagged HK$4.6bn ($588m) after sealing its Hong Kong public offering at the top of the price guidance.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: